Avelumab plus axitinib for translocation renal cell carcinoma: A case series and literature review
Kenta Takahashi, Renpei Kato, Daiki Ikarashi, Tomohiko Matsuura, Shigekatsu Maekawa, Mitsugu Kanehira, Ryo Takata, Jun Sugimura, Takaya Abe, Wataru Obara- Urology
Introduction
Patients with translocation renal cell carcinoma (tRCC) have a poor prognosis without standardized treatment.
Case presentation
The first case was of a 72‐year‐old woman who underwent robot‐assisted partial nephrectomy for a left renal tumor and was pathologically diagnosed with tRCC. Recurrence was observed in the left retroperitoneal soft tissue. After treatment with avelumab–axitinib, continued progression‐free survival was confirmed at the 90‐week follow‐up. The second case was of a 41‐year‐old woman referred to our hospital and presented with translocation renal cell carcinoma metastasis to a para‐aortic lymph node. After treatment with avelumab–axitinib, continued progression‐free survival was confirmed at the 43‐week follow‐up.
Conclusion
The outcomes of these cases indicate that avelumab–axitinib therapy has a long‐term antitumor effect in some patients with tRCC.